Exane Derivatives grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 888.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 3,953 shares of the medical research company’s stock after buying an additional 3,553 shares during the period. Exane Derivatives’ holdings in Amgen were worth $687,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the period. Hudock Capital Group LLC increased its position in Amgen by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after purchasing an additional 10 shares during the period. South Texas Money Management Ltd. increased its position in Amgen by 0.7% during the 2nd quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock worth $555,000 after purchasing an additional 22 shares during the period. Burt Wealth Advisors increased its position in Amgen by 0.8% during the 2nd quarter. Burt Wealth Advisors now owns 3,040 shares of the medical research company’s stock worth $523,000 after purchasing an additional 25 shares during the period. Finally, Hanson McClain Inc. increased its position in Amgen by 1.2% during the 2nd quarter. Hanson McClain Inc. now owns 2,195 shares of the medical research company’s stock worth $378,000 after purchasing an additional 25 shares during the period. Institutional investors own 78.61% of the company’s stock.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the sale, the executive vice president now owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 4,575 shares of company stock worth $818,361. 0.19% of the stock is owned by insiders.
Several equities analysts have issued reports on the company. Vetr cut Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price on the stock. in a research report on Tuesday. Mizuho upped their price target on Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Atlantic Securities cut Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target on the stock. in a report on Monday, February 5th. JPMorgan Chase & Co. restated a “hold” rating and issued a $191.00 price target on shares of Amgen in a report on Sunday, February 4th. Finally, Leerink Swann restated a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the company’s stock. Amgen has a consensus rating of “Hold” and a consensus price target of $191.72.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $190.35 on Wednesday. The company has a market capitalization of $137,000.50, a price-to-earnings ratio of 74.07, a price-to-earnings-growth ratio of 2.27 and a beta of 1.37. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a fifty-two week low of $152.16 and a fifty-two week high of $201.23.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. Amgen’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the company posted $2.89 EPS. equities research analysts forecast that Amgen, Inc. will post 13.21 earnings per share for the current year.
Amgen declared that its Board of Directors has authorized a share repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.77%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is 205.45%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).